Several
approved therapeutic products, which are currently available as intravenous
dosage forms, are being reformulated and evaluated for subcutaneous administration.
Further, many existing drug delivery devices, including prefilled syringes, pen
injectors, auto injectors, needle-free injectors and large volume wearable
injectors, have been / are being designed for subcutaneous administration of
biologics.
The USD 180+ billion (by
2030) financial opportunity associated with subcutaneous biologics, affiliated
drug delivery systems and subcutaneous formulation technology licensing deals,
has been analyzed across the following segments:
Subcutaneous Biologic Drugs and
Affiliated Technologies Market, Trends by 2030
Market
Segment:
Phase
of development
·
Approved
·
Pre-registration & Phase III
·
Phase II & Phase II/III
Type
of molecule
·
Cell and gene therapies
·
Monoclonal antibodies
·
Proteins
·
Peptides (recombinant)
·
Vaccines
·
Others
Target
therapeutic area
·
Autoimmune disorders
·
Blood disorders
·
Bone disorders
·
Genetic disorders
·
Metabolic disorders
·
Neurological disorders
·
Oncological disorders
·
Respiratory disorders
·
Others
Type
of drug delivery system
·
Large volume wearable injectors
·
Autoinjectors
·
Prefilled syringes
·
Needle-free injectors
·
Drug reconstitution systems
·
Revenues from licensing deals
·
Upfront payments
·
Milestone payments
Key
geographical regions
·
North America
·
Europe
·
Asia Pacific
·
Rest of the World
